Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DXC018 in Advanced Solid Tumors
NCT07849218Phase 1Not yet recruiting
- Sponsor
- Hangzhou DAC Biotech
- Start
- Oct 2026
- Primary completion
- Aug 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DXC018 in solid tumor, sponsored by Hangzhou DAC Biotech. Primary endpoints: Dose Limiting Toxicities at 28 days, Maximum Tolerated Dose up to 2 years and 2 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
DXC018
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07849218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07849218.